31 results about "Haem Oxygenase" patented technology

The present invention relates to a method for the prevention of allograft rejection in clinical transplantation. Specifically, the method of the present invention relates to the prevention of transplant arteriosclerosis and interstitial fibrosis by stable and long-term expression of HO-1 in grafts. The present invention represents a novel therapeutic approach to prevent allograft rejection in clinical transplantation.

The present invention relates to hybrid fumarate-CO-releasing molecules capable of increasing heme oxygenase-1 (HO-1) activity and HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases.

The invention provides a nanogel drug carrier for targeted delivery and consumption of a large amount of H2O2 and release of CO at the same time, and a preparation method and application thereof. Thenanogel drug carrier is a dendritic polypeptide nanogel drug carrier. The drug carrier comprises dendritic polypeptide nanogel as a carrier, and a carbon monoxide release molecules CORM401 loaded in an internal cavity of the dendritic polypeptide nanogel, and also comprises hyaluronic acid which is modified by folic acid and coats the surface of the dendritic polypeptide nanogel. A multifunctionalanti-inflammatory drug (CPHs) is prepared on the basis of the nanogel drug carrier disclosed by the invention. The drug carrier can enter activated macrophages in a HA-FA targeting manner, and rapidly release a large amount of CO is by consuming excessive H2O2. The generated CO not only can effectively inhibit cell proliferation, but also can obviously inhibit secretion of inflammatory factors byinducing activation (HO-1) of heme oxygenase and down-regulating expression of p38MAPK, NF-kB (p50 / p65) and TLR-2. The CPHs can consume a large amount of ROS at the osteoarthritis joint part, and effectively inhibit degradation of articular cartilage and extracellular matrix.

The invention discloses an exosome delivery carrier as well as a preparation method and application thereof, and relates to the field of medical treatment. The exosome can target heme oxygenase 1 (HMOX1) through HSSP polypeptide modification, HMOX1 protein is highly expressed in various tumor cells and neurodegenerative diseases, especially drug-resistant glioma, based on this, the exosome modified with HSSP can specifically target tumors and neurodegenerative diseases, and therefore, the exosome delivery carrier can also be applied to targeted therapy or prevention of tumors and / or neurodegenerative diseases, and a new solution is provided for the problem of drug resistance of glioma drugs TMZ. The exosome has extremely low immunogenicity, so that the safety of the delivery carrier is improved; meanwhile, the exosome also has good blood-brain barrier penetrating ability, so that the problem that the medicine is difficult to penetrate through the blood-brain barrier is solved.

The invention relates to a bismuth sulfide-zinc protoporphyrin composite material with a tumor photodynamic therapy (PDT) property under excitation of near-infrared light as well as a preparation method and application and belongs to the field of composite materials, aiming at solving the problem that the PDT efficiency is relatively low, caused by photoelectron-hole compounding in a photodynamictherapy process of bismuth sulfide and an anti-oxidization stress capability of heme oxygenase (HO-1) in cells. The composite material is the bismuth sulfide-zinc protoporphyrin composite material which is obtained by synthesizing a polyN-isopropylacrylamide-acrylamide copolymer modified bismuth sulfide nano-material and then carrying out condensation reaction of carboxyl and amino. The prepared composite material has the effect of enhancing the photodynamic therapy efficiency through two ways of inhibiting the activity of the heme oxygenase and promoting electron-hole separation; meanwhile, the material provided by the invention has good biocompatibility, light stability, CT (Computed Tomography) imaging capability and enhanced PDT efficiency; a thought is provided for designing a novel nano diagnosis and treatment integrated system and the material has important meaning on early-stage diagnosis and treatment of cancers.

The invention relates to the technical field of bilirubin production methods and discloses a method for synthesizing bilirubin by utilizing an immobilized enzyme. The method comprises the following steps of: a) respectively cloning haem oxygenase genes and biliverdin reductase genes; b) respectively expressing the recombinant haem oxygenase and biliverdin reductase in escherichia coli; c) extracting a crude extract or pure enzyme of haem oxygenase and a crude extract or pure enzyme of biliverdin reductase; d) immobilizing the crude extract or pure enzyme of haem oxygenase and the crude extract or pure enzyme of biliverdin reductase; and e) preparing bilirubin in the assistance of an oxidized coenzyme II by catalyzing with the immobilized haem oxygenase and the immobilized biliverdin reductase and taking haem and oxygen as substrates.

Disclosed are compounds of the general formula (I):compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

Heme released as a result of sustained injury leads to toxicity and triggers an inflammatory response and tissue damage. Heme oxygenase, an enzyme, recognizes, binds free heme and breaks it down as a part of the anti-inflammatory response. The present disclosure relates to a class of peptide amphiphiles that mimic the heme oxygenase function, and have shown that the designed peptide is able to bind and break down heme thus validating its potential as an anti-inflammatory agent that promotes tissue repair and useful in wound healing. The disclosed peptide sequence design provides control of amphiphile peptides' supramolecular structure and function. Applicants have shown that the incorporated heme molecule can transport CO, which suggests that the peptides can also transport NO, O2 and reactive oxygens, the molecules which are responsible for vasodilation, neurotransmission and cell death. Besides heme oxygenase function, it is believed that the designed peptides can recognize normal tissue adjacent to the damaged area and the peptide can self-assemble into fibers that promote healthy cell growth.

The present invention relates to hybrid fumarate-CO-releasing molecules capable of increasing heme oxygenase-1 (HO-1) activity and HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases.

Increased viral particle maturation and production can be achieved in various methods for producing viral particles from viral proteins, in general, by inhibiting or preventing Heme Oxygenase 2 (HO-2) from binding to the group-specific antigen (Gag) of the viral proteins, thus allowing delivery of the viral proteins to plasma membranes where they can replicate and mature without interference from HO-2. The increase in viral particle maturation and production can also be achieved by minimizing or eliminating the presence of HO-2 to thus reduce or prevent binding of HO-2 to the group-specific antigen (Gag) of the viral proteins. The invention is particularly applicable to the production of lentiviruses from viral proteins wherein the Matrix domain (MA) of the Gag is myristoylated.

The invention belongs to the technical field of gene engineering, and particularly discloses a heme oxygenase gene and an effect of the heme oxygenase gene in regulation and control of ganoderma lucidum polysaccharide biosynthesis. According to the invention, a ganoderma lucidum HMX1 gene is silenced through a gene silencing technology, so that ganoderma lucidum polysaccharide biosynthesis amountcan be increased. Besides, an RNA interference means is adopted so as to provide an important genetic manipulation means for improving the biosynthesis of the ganoderan by silencing the heme oxygenasegene; and thus, a theoretical basis is provided for improving the ganoderma lucidum polysaccharide biosynthesis by using a genetic engineering technical means.

The invention discloses application of an HO (Heme Oxygenase)-1 inhibitor in preparing medicine for treating cardiotoxicity induced by anti-cancer medicine-doxorubicin. The HO-1 inhibitor is zinc protoporphyrin. According to the application disclosed by the invention, basis is provided for new drug research and development and innovative therapy.

Increased viral particle maturation and production can be achieved in various methods for producing viral particles from viral proteins, in general, by inhibiting or preventing Heme Oxygenase 2 (HO-2) from binding to the group-specific antigen (Gag) of the viral proteins, thus allowing delivery of the viral proteins to plasma membranes where they can replicate and mature without interference from HO-2. The increase in viral particle maturation and production can also be achieved by minimizing or eliminating the presence of HO-2 to thus reduce or prevent binding of HO-2 to the group-specific antigen (Gag) of the viral proteins. The invention is particularly applicable to the production of lentiviruses from viral proteins wherein the Matrix domain (MA) of the Gag is myristoylated.

The invention relates to cobalt porphyrin / porous silicon dioxide composite particle with photoacoustic imaging performance and a cytoprotection function and a preparation method and application thereof. The preparation method comprises the steps that a cobalt ion-centered metallic porphyrin compound and porous silicon dioxide nano particles are mixed and stirred, particles are centrifugally collected and dried, and the multifunctional cobalt porphyrin / porous silicon dioxide composite particle is obtained. According to the preparation method, the metallic porphyrin compound is carried by the porous silicon dioxide nano particles, an optical absorption property of a porphyryl compound is changed, the absorption of molecule near an infrared light area is promoted, and an expressed photoacoustic imaging radiography performance is good. According to the composite material, haem oxygenase-1 can be up-regulated to generate a cytoprotection effect, and the survival rate of a cell after cell transplantation is improved. The adopted preparation method is simple, quick, economical, applicable and has high repeatability, the photoacoustic imaging and the cytoprotection are successfully combined, a new method for an imaging mark is provided and improves the cell survival rate.

The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. (Formula I) The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.

The invention belongs to the technical field of genetic engineering, and specifically discloses a heme oxygenase gene and its function in regulating the biosynthesis of ganoderma lucidum polysaccharide. Through gene silencing technology, the Ganoderma lucidum HMX1 gene was silenced to increase the biosynthesis of Ganoderma lucidum polysaccharides. This patent provides an important genetic operation method to improve the biosynthesis of Ganoderma lucidum polysaccharide by silencing the heme oxygenase gene by means of RNA interference, and provides a theoretical basis for improving the biosynthesis of Ganoderma lucidum polysaccharide by means of genetic engineering technology.